Literature DB >> 19527550

A modified case-control study of cryptosporidiosis (using non-Cryptosporidium-infected enteric cases as controls) in a community setting.

K D M Pintar1, F Pollari, D Waltner-Toews, D F Charron, S A McEwen, A Fazil, A Nesbitt.   

Abstract

Data from the first sentinel site (Waterloo Region, Ontario) of the Canadian Integrated Enteric Disease Surveillance System (C-EnterNet) were used in a secondary-based case-control study of laboratory-confirmed Cryptosporidium infections to study the role of various exposure factors. The incidence of cryptosporidiosis in Waterloo Region was almost double both the provincial and national rates. Persons ill with one of nine other enteric infections (amoebiasis, campylobacteriosis, cyclosporiasis, giardiasis, listeriosis, salmonellosis, shigellosis, verotoxigenic E. coli infections, yersiniosis) captured by the surveillance system were used as the control group. Of 1204 cases of enteric illness in the sentinel area between April 2005 and December 2007, 36 cases and 803 controls were selected after excluding outbreak and international travel-related cases. Univariable analyses (Pearson chi2 and Fisher's exact tests) and multivariable logistic regression were performed. Results of the multivariable analysis found that cryptosporidiosis was associated with swimming in a lake or river (OR 2.9, 95% CI 1.2-7.4), drinking municipal water (a potential surrogate for urban respondents vs. rural) (OR 2.4, 95% CI 1.04-5.7), and having a family member with a diarrhoeal illness (OR 2.9, 95% CI 1.3-6.4).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527550     DOI: 10.1017/S0950268809990197

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  8 in total

Review 1.  Case-control studies of sporadic enteric infections: a review and discussion of studies conducted internationally from 1990 to 2009.

Authors:  Kathleen E Fullerton; Elaine Scallan; Martyn D Kirk; Barbara E Mahon; Frederick J Angulo; Henriette de Valk; Wilfrid van Pelt; Charmaine Gauci; Anja M Hauri; Shannon Majowicz; Sarah J O'Brien
Journal:  Foodborne Pathog Dis       Date:  2012-04       Impact factor: 3.171

Review 2.  Cryptosporidium pathogenicity and virulence.

Authors:  Maha Bouzid; Paul R Hunter; Rachel M Chalmers; Kevin M Tyler
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

3.  Epidemiological and clinical description of the top three reportable parasitic diseases in a Canadian community.

Authors:  A Ravel; A Nesbitt; K Pintar; A Macarthur; H-L Wang; B Marshall; F Pollari
Journal:  Epidemiol Infect       Date:  2012-05-25       Impact factor: 4.434

4.  Global distribution, public health and clinical impact of the protozoan pathogen cryptosporidium.

Authors:  Lorenza Putignani; Donato Menichella
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-07-14

5.  Case-case analyses of cryptosporidiosis and giardiasis using routine national surveillance data in the United States - 2005-2015.

Authors:  K M Benedict; S A Collier; E P Marder; M C Hlavsa; K E Fullerton; J S Yoder
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

6.  Molecular characterization of Cryptosporidium isolates from humans in Ontario, Canada.

Authors:  Rebecca A Guy; Christine A Yanta; Pia K Muchaal; Marisa A Rankin; Karine Thivierge; Rachel Lau; Andrea K Boggild
Journal:  Parasit Vectors       Date:  2021-01-22       Impact factor: 3.876

7.  Heavy precipitation, drinking water source, and acute gastrointestinal illness in Philadelphia, 2015-2017.

Authors:  Anneclaire J De Roos; Michelle C Kondo; Lucy F Robinson; Arjita Rai; Michael Ryan; Charles N Haas; José Lojo; Jerald A Fagliano
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

8.  Cross-sectional household transmission study of Cryptosporidium shows that C. hominis infections are a key risk factor for spread.

Authors:  Caoimhe McKerr; Rachel M Chalmers; Kristin Elwin; Heather Ayres; Roberto Vivancos; Sarah J O'Brien; Robert M Christley
Journal:  BMC Infect Dis       Date:  2022-02-02       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.